An observational study in Myotonic Dystrophy, Congenital Myotonic Dystrophy and Myotonic Dystrophy 1, sponsored by Myotonic Dystrophy Foundation. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by Myotonic Dystrophy Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 2nd largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2013, is one of 21 observational ones, reaches primary completion later than 20 of the 26 other live ones, and was the 10th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 5 started in 2013.
This study's planned enrollment of 3,500 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Myotonic Dystrophy Foundation as lead sponsor.
Myotonic Dystrophy Foundation has 1 study filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Myotonic Dystrophy Family Registry (MDFR) is an online, patient-entered database that collects information on myotonic dystrophy (DM) to aid researchers in developing new, effective treatments and help identify participants for research studies and clinical trials.
The Myotonic Dystrophy Family Registry (MDFR) is an online, patient-entered database that collects information on myotonic dystrophy (DM) such as disease symptoms and demographic information to aid researchers in developing new, effective treatments and help identify participants for research studies and clinical trials.
The Registry supports trials and studies, making it easier for researchers to explore data and identify possible trial and study participants. It is the first DM registry that gives community members the opportunity to explore anonymous Registry data, to see what the DM community looks like and what others with DM experience. It also provides information on the community of people living with DM, giving researchers and other medical professionals the opportunity to improve how they treat those affected with DM and learn more about how and why certain treatments work and don't work.
Participants will volunteer to participate in this study and enter their own information. The study will be advertised through neuromuscular disease clinics and the Myotonic Dystrophy Foundation and Myotonic Dystrophy Family Registry websites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This registry provides patient-entered data for future clinical trial and study use.
Patient reported outcomes
Number of patients reporting specific symptoms and symptom severity, as well as impacts to quality of life and overall burden of disease in order to inform clinical trial development, understanding of disease for academic, industry and federal agency stakeholders and overall policy decisions. Results will be analyzed in comparison to other registry data and surveys to characterize this disease population cohort and to further define the population.
Time frame: 36 months
The record gives a start of Feb 2013, a primary completion of Feb 2030 and a completion of Feb 2030. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.